Image: Shutterstock
February 14, 2024 09:00 AM EST
Bioregnum

We just had a string of suc­cess­ful biotech IPOs. Now what?

When CG On­col­o­gy’s $CGON IPO hit a few weeks ago, its suc­cess with in­vestors star­tled a wide swathe of biotech watch­ers who …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

No­vo de­clares Phase 3 car­diac out­comes tri­al win for oral GLP-1

Star­board takes ac­tivist stake in J&J con­sumer spin­out Ken­vue

For­mer Karuna crew quick­ly as­sem­bles $225M for next neu­ro bet at Sea­port

Q3 biotech roundup: The 2024 turn­around sput­ters in­to a crit­i­cal Q4 fi­nale

As­traZeneca-backed CD­MO Nu­cle­us Ra­dio­Phar­ma to boost com­mer­cial ca­pac­i­ty

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times